Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYAD

Celyad (CYAD) Stock Price, News & Analysis

Celyad logo

About Celyad Stock (NASDAQ:CYAD)

Advanced Chart

Key Stats

Today's Range
$0.40
$0.65
50-Day Range
$0.59
$0.85
52-Week Range
$0.46
$3.07
Volume
3,009 shs
Average Volume
N/A
Market Capitalization
$15.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad and its competitors with MarketBeat's FREE daily newsletter.

CYAD Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Celyad Oncology Announces Strategic Review
Celyad Oncology to Present at the 2024 SITC Annual Meeting
See More Headlines

CYAD Stock Analysis - Frequently Asked Questions

Celyad (CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celyad investors own include Galapagos (GLPG), Cellectis (CLLS), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), bluebird bio (BLUE), Bristol Myers Squibb (BMY) and ChromaDex (CDXC).

Company Calendar

Today
7/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAD
Employees
95
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$200 thousand
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
30.00

Miscellaneous

Free Float
26,276,000
Market Cap
$15.91 million
Optionable
Not Optionable
Beta
N/A

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CYAD) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners